CIK 0001720580
- Non-accelerated filer
- Smaller reporting company
Adicet Bio, Inc.
Sign in to watch- Ticker
- ACET
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 26
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813305277
- Phone
- +1 617-482-2333
- Business address
- 131 DARTMOUTH STREET, 3RD FLOOR, BOSTON, MA, 02116
- Former names
- resTORbio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-05 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +375,077 | 375,077 | ||
| 2024-01-24 | Galimi Francesco SVP & Chief Medical Officer | Shares withheld for taxes | −4,957 | $2.40 | $12K | 75,501 |
| 2024-01-24 | Galimi Francesco SVP & Chief Medical Officer | Grant or award | +26,300 | 101,801 | ||
| 2024-01-24 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +288,134 | 288,134 | ||
| 2023-10-02 | Galimi Francesco SVP & Chief Medical Officer | Shares withheld for taxes | −8,093 | $1.37 | $11K | 80,458 |
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −113,652 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +113,652 | 113,652 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −77,269 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +77,269 | 77,269 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −73,964 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +73,964 | 73,964 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −26,625 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +26,625 | 26,625 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −125,000 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −117,200 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +117,200 | 117,200 | ||
| 2023-01-24 | Galimi Francesco SVP & Chief Medical Officer | Grant or award | +26,100 | 88,551 | ||
| 2023-01-24 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +117,200 | 117,200 | ||
| 2022-10-04 | Galimi Francesco SVP & Chief Medical Officer | Shares withheld for taxes | −7,933 | $14.22 | $113K | 62,451 |
Page 1 of 3 · 46 trades